Busting the Myth of "Static vs Cidal": A Systemic Literature Review
- PMID: 29293890
- PMCID: PMC5905615
- DOI: 10.1093/cid/cix1127
Busting the Myth of "Static vs Cidal": A Systemic Literature Review
Abstract
We sought to determine if clinical data validate the dogma that bactericidal antibiotics are more clinically effective than bacteriostatic agents. We performed a systematic literature review of published, randomized, controlled trials (RCTs) that compared a bacteriostatic agent to a bactericidal agent in the treatment of clinical, bacterial infections. Of 56 identified trials published since 1985, 49 found no significant difference in efficacy between bacteriostatic and bactericidal agents. In 6 trials it was found that the bacteriostatic agent was superior to the bactericidal agent in efficacy. Only 1 trial found that the bactericidal agent was superior; in that case, the inferiority of the static agent was explainable by underdosing of the drug based on pharmacokinetic-pharmacodynamic analysis. Thus, virtually all available data from high-quality, RCTs demonstrate no intrinsic superiority of bactericidal compared to bacteriostatic agents. Other drug characteristics such as optimal dosing, pharmacokinetics, and tissue penetration may be more important efficacy drivers.
Comment in
-
Static vs Cidal Antibiotics.Clin Infect Dis. 2019 Jan 7;68(2):351-352. doi: 10.1093/cid/ciy645. Clin Infect Dis. 2019. PMID: 30099494 No abstract available.
-
Reply to Steigbigel and Steigbigel.Clin Infect Dis. 2019 Jan 7;68(2):352-353. doi: 10.1093/cid/ciy646. Clin Infect Dis. 2019. PMID: 30099501 No abstract available.
References
-
- Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin Infect Dis 2004; 38:864–70. - PubMed
-
- Freire AT, Melnyk V, Kim MJ et al. ; 311 Study Group Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68:140–51. - PubMed
-
- Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013; 57:1756–62. - PMC - PubMed
-
- Breedt J, Teras J, Gardovskis J et al. ; Tigecycline 305 cSSSI Study Group Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49:4658–66. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical